利钠肽、体重指数与射血分数轻度降低或保留心衰的临床结局
该研究 pooled 分析了 4 项随机对照试验中 14,750 例 HFmrEF/HFpEF 患者,评估 NT-proBNP 与临床结局的关联是否受 BMI 影响。结果发现基线 BMI 越高,NT-proBNP 水平非线性降低,且 NT-proBNP 与心血管死亡或心衰住院的关联随 BMI 升高而减弱。结论提示当前 NT-proBNP 阈值在高 BMI 患者中低估了绝对风险,可能需要更低的切点进行风险分层。
要点
- 高 BMI 与较低 NT-proBNP 水平非线性相关,NT-proBNP 每翻倍对应心血管死亡或心衰住院风险增加 40%。
- NT-proBNP 与结局的关联随 BMI 升高而逐渐减弱(交互 P=0.008)。
- 相同绝对风险下,高 BMI 患者所需 NT-proBNP 阈值更低,固定切点可能低估高 BMI 患者风险。
核心结论
- 当前 NT-proBNP 阈值在高 BMI 的 HFmrEF/HFpEF 患者中显著低估了不良心衰结局的绝对风险。
- 研究质疑单一固定阈值,建议对高 BMI 患者采用更低的 NT-proBNP 切点进行风险分层。
研究设计与样本
- 参与者水平 pooled 分析,纳入 4 项全球随机对照结局试验(I-PRESERVE、TOPCAT、PARAGON-HF、DELIVER)。
- 共纳入 14,750 例 HFmrEF/HFpEF 成人,平均年龄 72±9 岁,50% 女性,平均 BMI 30±6 kg/m2,中位 NT-proBNP 836 pg/mL。
主要发现
- 基线 BMI 越高,NT-proBNP 水平非线性显著降低。
- 中位随访 2.8 年,基线 NT-proBNP 每翻倍与协变量校正后心血管死亡或心衰住院率增加 40% 相关(HR: 1.40; 95% CI: 1.36-1.43; P < 0.001)。
- 该关联随基线 BMI 升高而逐渐减弱(Pinteraction = 0.008)。
- 无房颤患者中,达到相同绝对风险(5 事件/100 人年)时,BMI ≥35 kg/m2 者 NT-proBNP 为 158 pg/mL,而 BMI <35 kg/m2 者为 450 pg/mL,前者约为后者的近 1/3。
- 在当代基于 NT-proBNP 的试验入选阈值下,心血管死亡或心衰住院绝对风险从 BMI <30 kg/m2 者的 3.5/100 人年升至 BMI ≥40 kg/m2 者的 7.3/100 人年。
临床怎么用
- 对高 BMI 的 HFmrEF/HFpEF 患者,应认识到固定 NT-proBNP 阈值可能低估其绝对风险,考虑采用更低的切点辅助风险分层。
- 临床解读 NT-proBNP 时应结合 BMI 进行个体化评估,避免仅依赖单一固定阈值决定试验入选或治疗强度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Natriuretic peptides are the primary biomarkers recommended in heart failure (HF) guidelines to risk stratify patients in clinical practice and serve as key eligibility criteria in contemporary clinical trials. However, threshold levels typically do not account for measures of adiposity, such as body mass index (BMI). OBJECTIVE: The purpose of this study was to evaluate the association between N-terminal pro-B-type natriuretic peptide (NT-proBNP) with clinical outcomes in individuals with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), stratified according to BMI. METHODS: In this participant-level pooled analysis of 4 global, randomized, outcomes trials including adults with HFmrEF/HFpEF, the association between NT-proBNP and clinical outcomes (cardiovascular death or HF hospitalization, cardiovascular death, and all-cause death) was evaluated according to BMI as a continuous and categorical variable. RESULTS: Among 14,750 participants (mean age, 72 ± 9 years; 50% female; mean BMI, 30 ± 6 kg/m2; median NT-proBNP, 836 pg/mL), higher baseline BMI was significantly and nonlinearly associated with lower NT-proBNP levels. Over a median follow-up of 2.8 years, each doubling of baseline NT-proBNP was associated with a 40% higher covariate-adjusted rate of cardiovascular death or HF hospitalization (HR: 1.40; 95% CI: 1.36-1.43; P < 0.001); however, this association appeared incrementally blunted with higher baseline BMI (Pinteraction = 0.008). For the same absolute risk of cardiovascular death or HF hospitalization (5 events per 100 person-years), NT-proBNP levels in participants without atrial fibrillation were nearly 3-fold lower among those with BMI ≥35 kg/m2 (158 pg/mL) vs <35 kg/m2 (450 pg/mL). At a contemporary NT-proBNP-based trial eligibility threshold, absolute risk of cardiovascular death or HF hospitalization ranged from 3.5 per 100 person-years among persons with BMI <30 kg/m2 to 7.3 per 100 person-years among those with BMI ≥40 kg/m2. CONCLUSIONS: In this analysis, current NT-proBNP thresholds substantially underestimated the absolute risk of adverse HF outcomes among persons with higher BMI. These data question single fixed thresholds and instead suggest that lower NT-proBNP cutoffs may more appropriately risk stratify patients with higher BMI. (Irbesartan in Heart Failure and Preserved Ejection Fraction [I-PRESERVE], NCT00095238; Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist [TOPCAT], NCT00094302; Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor with Angiotensin Receptor Blocker Global Outcomes in HF with Preserved Ejection Fraction [PARAGON-HF], NCT01920711; Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure [DELIVER], NCT03619213).
引用
- Ostrominski JW, Neuen BL, Claggett BL, et al. Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. J Am Coll Cardiol. 2025. PMID: 40892613. doi:10.1016/j.jacc.2025.08.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。